Filing summary
Issuer discrepancy: The supplied filing is Zafgen, Inc.’s Form 10-Q, not a Larimar Therapeutics, Inc. filing. It covers the quarter ended March 31, 2019; Zafgen traded as ZFGN on Nasdaq. Confirm the issuer and filing before relying on this summary.
Business context and reporting period
Zafgen was a clinical-stage biopharmaceutical company developing MetAP2 inhibitors for metabolic diseases. It reported no product revenue and had no approved products. Its lead candidate, ZGN-1061, was in Phase 2 development; ZGN-1258 and ZGN-1345 were in nonclinical development.
Financial performance and position
| Metric | Q1 2019 | Q1 2018 or prior balance-sheet date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $9.6 million | $12.4 million |
| General and administrative expense | $3.6 million | $3.3 million |
| Total operating expenses | $13.3 million | $15.7 million |
| Net loss | $13.1 million | $16.0 million |
| Basic and diluted loss per share | $0.35 | $0.58 |
| Cash used in operating activities | $12.5 million | $13.3 million |
| Cash, cash equivalents and marketable securities | $104.7 million | $118.1 million at December 31, 2018 |
| Total debt carrying value | Approximately $20.8 million | Approximately $20.8 million at December 31, 2018 |
At March 31, 2019, total assets were $110.2 million, total liabilities $27.8 million, and stockholders’ equity $82.4 million. Cash and cash equivalents were $36.4 million, marketable securities $68.2 million, and restricted cash $1.3 million. The term loan had $20.0 million principal outstanding; scheduled principal repayments began in April 2019. The company reported no product-sales margin; profitability and operating margins were negative given the absence of revenue and ongoing development costs.
Material changes versus the prior comparable period
- Net loss narrowed by $2.8 million year over year. Operating expenses fell $2.4 million, principally as ZGN-1061 clinical-trial costs declined; higher interest income also contributed.
- R&D expense declined $2.8 million, including a $1.9 million reduction in ZGN-1061 clinical costs. G&A expense increased $0.4 million, mainly from personnel and stock-based compensation.
- Operating cash use improved by $0.8 million year over year. Cash, cash equivalents and restricted cash decreased $11.6 million during Q1 2019.
- Cash, cash equivalents and marketable securities declined $13.4 million from year-end 2018. A new lease accounting standard added $0.9 million in operating lease right-of-use assets and liabilities.
Outlook, commentary, risks and unusual items
- Management expected available cash, cash equivalents and marketable securities to fund planned operations, capital expenditures and debt requirements for at least 12 months from the May 9, 2019 filing date. It also expected continuing operating losses and anticipated needing additional financing over time; no revenue or earnings guidance was provided.
- The FDA had placed a full clinical hold on the U.S. IND for ZGN-1061, citing potential cardiovascular safety risk in light of the company’s prior compound. The filing gave no resolution date. Management said completed ex-U.S. Phase 1 and Phase 2 trials had shown no cardiovascular safety signals and expected to present full Phase 2 results at a 2019 medical meeting.
- In March 2019, Zafgen suspended plans to file an IND for ZGN-1258 while evaluating unexpected muscle-tissue degeneration in long-term rat toxicology studies. The company reported the finding was absent in other long-term animal models and appeared specific to ZGN-1258.
- ZGN-1345 had advanced to development-candidate status; further nonclinical studies were ongoing. Management described preliminary nonclinical results in liver disease indications as positive.
- The $20.0 million Silicon Valley Bank term loan carried a variable rate of prime plus 1.25% (5.5% prime at quarter-end), plus an 8% final payment. Minimum liquidity and other covenants apply; failure to meet specified requirements could accelerate repayment or trigger lender remedies.
- A February 2019 Boston headquarters lease covers approximately 17,705 square feet for an initial 124 months, with $10.7 million of stated total lease payments. The commencement date had not been determined by quarter-end; $1.3 million of restricted cash supported a letter of credit.
- The company disclosed no material litigation and no material off-balance-sheet arrangements. It had an at-the-market equity sales agreement for up to $50 million, but had sold no shares under it through March 31, 2019.
Most important facts for investors to verify
- Whether this Zafgen filing is the intended filing, given the Larimar Therapeutics metadata.
- Current status and FDA requirements for the ZGN-1061 clinical hold, including any cardiovascular-safety work required to lift it.
- Results of the ZGN-1258 toxicology evaluation and whether its development continues.
- Cash runway assumptions, debt-covenant compliance, scheduled repayments, and any subsequent financing or ATM share sales.
- The commencement, cash costs and obligations under the new headquarters lease.